氧化和Elobixibat对改善慢性便秘患者的直肠敏感性和结肠过渡时间的疗效的比较:一项观察性研究
Takaomi Kessoku1,2,3,4, Yo Ishihara1,2,3,4, Kota Takahashi1,2,3,4
1Department of Palliative Medicine and Gastroenterology, International University Health and Welfare Narita Hospital, Chiba, Japan.
Neurogastroenterology and motility
|June 24, 2025
概括
在慢性便秘患者中,Elobixibat (EXB) 比氧化 (MgO) 显著改善了便秘欲望的丧失,直肠感觉和结肠过境时间. 这项研究提供了关于便秘治疗选择的见解.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 慢性便秘 (CC) 影响了相当一部分人口.
- 了解不同治疗CC的比较疗效对于临床实践至关重要.
研究的目的:
- 为了比较氧化物 (MgO) 和氧化物 (EXB) 在治疗慢性便秘症状方面的有效性.
- 评估MGO和EXB对排便欲望,直肠感觉和结肠过境时间的影响.
主要方法:
- 在现实世界的临床环境中进行前性观察性研究.
- 包括符合罗马四号标准的CC患者.
- 使用放射性不透明标记器评估排便欲望丧失 (LODD),第一次排便欲望量 (FDDV) 和结肠过境时间 (CTT).
主要成果:
- 与氧化 (MgO) 相比,Elobixibat (EXB) 组在LODD (65%对33%) 中的改善率显著更高.
- EXB导致FDDV的绝对变化更大 (35mL与-0.1mL),表明直肠感觉得到改善.
- 从缓慢过渡便秘 (STC) 转变为正常过渡便秘 (NTC) 的转变率在EXB (87%与37%相比) 中显著更高.
结论:
- 埃洛比西巴特 (EXB) 在改善慢性便秘的关键参数方面表现出比氧化 (MgO) 更高的疗效.
- EXB在增强排便欲望,直肠感觉和结肠过境时间方面提供了显著的好处.
- 这些发现支持使用EXB作为慢性便秘患者更有效的治疗选择.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
353
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
353
Drugs for Treatment of Diarrhea-Predominant IBS
313
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
313
Drugs Affecting GI Tract Motility: Other Laxatives
479
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
479
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
307
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
307
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
325
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
325
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
418
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
418


